Sunitinib for the management of advanced renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 10, Issue 3, 2010, Pages 305-317

  Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Kidney cancer; Metastatic; PDGF; Renal cell carcinoma; Sunitinib; Tyrosine kinase inhibitor; VEGF

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; CANCER LOCALIZATION; CELL DEATH; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INTERACTION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPISTAXIS; ERYTHEMA; EXTREMITY PAIN; FATIGUE; FEVER; FLATULENCE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GLOSSODYNIA; GOUT; HAIR COLOR; HAND FOOT SYNDROME; HEADACHE; HEART EJECTION FRACTION; HEART FAILURE; HISTOLOGY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNOTHERAPY; KIDNEY CARCINOMA; LEUKOPENIA; LYMPHOCYTOPENIA; METASTASIS; MOUTH PAIN; MUCOSAL INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHRECTOMY; OVERALL SURVIVAL; PERIPHERAL EDEMA; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL; TUMOR VASCULARIZATION; VASCULAR TOXICITY; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PRACTICE GUIDELINES AS TOPIC; PYRROLES;

EID: 77949429364     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.10.26     Document Type: Review

References (59)

1. Escudier B, Kataja V, on behalf of the ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20, iv81-iv82 (2009).
2. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18, 581-592 (2007).
3. Levi F, Ferlay J, Galeone C et al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int. 101, 949-958 (2008).
4. Pfizer Inc. SUTENT, summary of product characteristics. (2009).
5. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
6. Escudier B, Ravaud A, Oudard S et al. Phase-3 randomised trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma. Presented at the 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, 12-16 September 2008 (Abstract 72O).
7. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312-3318 (2009).
8. Escudier BJ, Bellmunt J, Negrier S et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-a2a (IFN) in metastaric renal cell carcinoma (mRCC). J. Clin. Oncol. 27 (2009) (Abstract 5020).
9. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
10. Kay A, Motzer RJ, Figlin RA et al. Updated data from a Phase 3 trial of everolimus (RAD001) versus placebo in patients with metastatic renal cell carcinoma. Eur. Urol. 8(Suppl.), 185 (2009).
11. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372, 449-456 (2008).
12. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib versus interferon a in first-line treatment of patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
13. Rini BI, Halabi S, Rosenberg J et al. Bevacizumab plus interferon-a versus interferon-a monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. J. Clin. Oncol. 27 (2009) (Abstract LBA5019).
14. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. (2010) (Epub ahead of print).
15. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003).
16. Kim DW, Jo YS, Jung HS et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/ papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab. 91, 4070-4076 (2006).
17. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor b in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2, 471-478 (2003).
18. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 14, 285-294 (2007).
19. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 3, 439-443 (2003).
20. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101, 3597-3605 (2003).
21. Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis 20, 757-766 (2003).
22. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844 (1993).
23. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6, 734-745 (2007).
24. Barrios CH, Hernandez-Barajas D, Brown MP et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Presented at the 8th International Kidney Cancer Symposium, Chicago, USA, 25-26 September 2009.
25. Escudier B, Roigas J, Gillessen S et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 27, 4068-4075 (2009).
26. Khosravan R, Toh M, LaFargue J, Ni G, Bello C. Sunitinib pharmacokinetic (PK) and safety data in subjects with renal impairment and on hemodialysis. J. Clin. Oncol. 26 (2008) (Abstract 2578).
27. Houk B, Bello C, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res. 5, 2497-2506 (2009).
28. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24, 25-35 (2006).
29. Houk BE, Bello CL, Poland B et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol. (2009) (Epub ahead of print).
30. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006).
31. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516-2524 (2006).
32. Motzer RJ, Michaelson MD, Rosenberg J et al. Sunitinib efficacy against advanced renal cell carcinoma. J. Urol. 178, 1883-1887 (2007).
33. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
34. Motzer RJ, Figlin RA, Hutson TE et al. Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, USA, 1-5 June 2007 (Abstract 5024).
35. Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. CD001425 (2005).
36. Cella D, Li JZ, Cappelleri JC et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J. Clin. Oncol. 26, 3763-3769 (2008).
37. Remak E, Charbonneau C, Negrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J. Clin. Oncol. 26, 3995-4000 (2008).
38. Benedict Á, Figlin RA, Charbonneau C. Economic evaluation of sunitinib vs. sorafenib and bevacizumab plus interferon-alfa among all patients and sunitinib vs. temsirolimus in poor-risk patients as first-line therapy of metastatic renal cell carcinoma in the US. Presented at the 8th International Kidney Cancer Symposium. Chicago, USA 25-26 September 2009.
39. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib with subpopulation analysis in an expanded-access trial of metastatic renal cell carcinoma. Lancet Oncol. 10, 757-763 (2009).
40. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 26, 127-131 (2008).
41. Plimack ER, Jonasch E, Bekele BN et al. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): a Phase II study. Presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, USA, 30 May-3 June 2008 (Abstract 5112).
42. Feldman DR, Baum MS, Ginsberg MS et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1432-1439 (2009).
43. Rini BI, Garcia JA, Cooney MM et al. A Phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin. Cancer Res. 15, 6277-6283 (2009).
44. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 7, 24-27 (2009).
45. Kroog GS, Feldman DR, Kondagunta GV, et al. Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, (2009) (Abstract 5037).
46. Amin C, Wallen E, Pruthi RS et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 72, 864-868 (2008).
47. Ansari J, Doherty A, McCafferty I et al. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma. Clin. Genitourin. Cancer 7, E39-E41 (2009).
48. Harshman LC, Srinivas S, Kamaya A, Chung BI. Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat. Rev. Urol. 6, 338-343 (2009).
49. Karakiewicz PI, Suardi N, Jeldres C et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur. Urol. 53, 845-848 (2008).
50. Robert G, Gabbay G, Bram R et al. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur. Urol. 55, 1477-1480 (2009).
51. Shuch B, Riggs SB, LaRochelle JC et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 102, 692-696 (2008).
52. Thomas AA, Rini BI, Lane BR et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 181, 518-523 (2009).
53. Bhojani N, Jeldres C, Patard JJ et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur. Urol. 53, 917-930 (2008).
54. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13, 1084-1096 (2008).
55. Ravaud A. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann. Oncol. 20(Suppl. 1), i7-i12 (2009).
56. Kollmannsberger C, Soulieres D, Wong R et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can. Urol. Assoc. J. 1, S41-S54 (2007).
57. Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann. Intern. Med. 145, 660-664 (2006).
58. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst. 99, 81-83 (2007).
59. Porta C, Szczylik C, Bracarda S et al. Short and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. J. Clin. Oncol. 26 (2008) (Abstract 5114).